Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial.
clinical trials
epidemiologic studies
guinea-bissau
ivermectin
malaria
mass drug administration
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
07 07 2023
07 07 2023
Historique:
medline:
10
7
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
As malaria declines, innovative tools are required to further reduce transmission and achieve elimination. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) is capable of reducing malaria transmission where coverage of control interventions is already high, though the impact is short-lived. Combining ACT with ivermectin, an oral endectocide shown to reduce vector survival, may increase its impact, while also treating ivermectin-sensitive co-endemic diseases and minimising the potential impact of ACT resistance in this context. MATAMAL is a cluster-randomised placebo-controlled trial. The trial is being conducted in 24 clusters on the Bijagós Archipelago, Guinea-Bissau, where the peak prevalence of The trial has been approved by the London School of Hygiene and Tropical Medicine's Ethics Committee (UK) (19156) and the Comite Nacional de Eticas de Saude (Guinea-Bissau) (084/CNES/INASA/2020). Results will be disseminated in peer-reviewed publications and in discussion with the Bissau-Guinean Ministry of Public Health and participating communities. NCT04844905.
Identifiants
pubmed: 37419638
pii: bmjopen-2023-072347
doi: 10.1136/bmjopen-2023-072347
pmc: PMC10335573
doi:
Substances chimiques
artenimol
6A9O50735X
Antimalarials
0
Ivermectin
70288-86-7
Artemisinins
0
Banques de données
ClinicalTrials.gov
['NCT04844905']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e072347Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S005013/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: JGL declares he is founder/CEO of Arctech Innovation, a company which aims to design mosquito lures and malaria diagnostics.
Références
PLoS Med. 2015 Mar 03;12(3):e1001788
pubmed: 25734259
Malar J. 2016 Dec 20;15(1):597
pubmed: 27998271
J Infect Dis. 2016 Dec 15;214(12):1831-1839
pubmed: 27923947
Lancet. 2019 Apr 13;393(10180):1517-1526
pubmed: 30878222
Lancet Infect Dis. 2022 Apr;22(4):519-528
pubmed: 34919831
Cochrane Database Syst Rev. 2014 Jan 20;(1):CD010927
pubmed: 24443033
Monogr Ser World Health Organ. 1962;47:13-191
pubmed: 13885800
Malar J. 2017 Apr 24;16(1):161
pubmed: 28434401
Trans R Soc Trop Med Hyg. 2009 Apr;103(4):342-6
pubmed: 19195671
Ophthalmic Epidemiol. 2015;22(3):190-9
pubmed: 26158577
Trop Med Parasitol. 1995 Jun;46(2):131-7
pubmed: 8525285
PLoS Negl Trop Dis. 2020 Dec 16;14(12):e0008938
pubmed: 33326420
Malar J. 2016 Feb 24;15:117
pubmed: 26911803
PLoS Negl Trop Dis. 2020 Apr 13;14(4):e0008037
pubmed: 32282815
J Infect Dis. 2010 Jul 1;202(1):113-6
pubmed: 20482251
J Clin Pharmacol. 2002 Oct;42(10):1122-33
pubmed: 12362927
Lancet Glob Health. 2017 Jul;5(7):e680-e687
pubmed: 28566213
Cochrane Database Syst Rev. 2021 Jun 29;6:CD013117
pubmed: 34184757
JMIR Res Protoc. 2016 Nov 17;5(4):e213
pubmed: 27856406
PLoS Negl Trop Dis. 2016 Jan 28;10(1):e0004380
pubmed: 26820626
Soc Sci Med. 2019 Jun;230:204-213
pubmed: 31030011
JAMA. 2017 May 16;317(19):2010-2011
pubmed: 28510677
Dental Press J Orthod. 2022 Jul 04;27(3):e2220290
pubmed: 35792787
Drugs. 2012 May 7;72(7):937-61
pubmed: 22515619
Malar J. 2020 Feb 13;19(1):70
pubmed: 32054502
Malar J. 2020 Jan 15;19(1):27
pubmed: 31941507
Clin Pharmacol Ther. 2020 May;107(5):1221-1230
pubmed: 31697848
Malar J. 2016 Jan 27;15:43
pubmed: 26818128
Lancet. 2019 Sep 21;394(10203):1005-1006
pubmed: 31324344
Malar J. 2022 Jun 11;21(1):186
pubmed: 35690758
J Infect Dis. 2014 Dec 15;210(12):1972-80
pubmed: 24951826
Malar J. 2014 Nov 03;13:417
pubmed: 25363349
Parasit Vectors. 2017 Dec 28;10(1):624
pubmed: 29282126
Parasit Vectors. 2021 Sep 15;14(1):474
pubmed: 34526120
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4438-47
pubmed: 26216993
Wellcome Open Res. 2019 Feb 8;4:26
pubmed: 32518839
Cochrane Database Syst Rev. 2021 Sep 29;9:CD008846
pubmed: 34585740
Sci Rep. 2017 May 25;7(1):2398
pubmed: 28546554
Clin Infect Dis. 2015 Feb 1;60(3):357-65
pubmed: 25414262
Bull World Health Organ. 1987;65(1):39-45
pubmed: 3555879
Lancet Infect Dis. 2020 Apr;20(4):498-508
pubmed: 31948767
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Trans R Soc Trop Med Hyg. 2005 Apr;99(4):279-89
pubmed: 15708387
Nature. 2015 Oct 8;526(7572):207-211
pubmed: 26375008
Lancet Infect Dis. 2018 Jun;18(6):615-626
pubmed: 29602751
PLoS Med. 2010 Aug 10;7(8):
pubmed: 20711482
Br J Clin Pharmacol. 2004 Mar;57(3):253-62
pubmed: 14998421
Trans R Soc Trop Med Hyg. 2004 Aug;98(8):496-504
pubmed: 15186939
Philos Trans R Soc Lond B Biol Sci. 2021 Feb 15;376(1818):20190807
pubmed: 33357055
PLoS Genet. 2017 Feb 2;13(2):e1006539
pubmed: 28151952
Sci Rep. 2023 Apr 18;13(1):6311
pubmed: 37072433
Trials. 2015 Aug 13;16:347
pubmed: 26268804
Nat Rev Microbiol. 2014 Dec;12(12):833-40
pubmed: 25329408
Med Vet Entomol. 2002 Dec;16(4):461-4
pubmed: 12510902
Acta Trop. 2014 Oct;138:78-82
pubmed: 25051188
Malar J. 2014 Mar 21;13:111
pubmed: 24656206
N Engl J Med. 2016 Mar 10;374(10):913-27
pubmed: 26962727
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5108-13
pubmed: 15792998
Am J Trop Med Hyg. 2015 Nov;93(5):961-6
pubmed: 26240155
Malar J. 2020 Nov 17;19(1):412
pubmed: 33203419
Clin Infect Dis. 2019 Jul 2;69(2):278-286
pubmed: 30304511
Am J Trop Med Hyg. 2011 Feb;84(2):338-43
pubmed: 21292911